112 related articles for article (PubMed ID: 38186002)
1. Fatty acid metabolism-related molecular subtypes and a novel model for predicting prognosis in bladder cancer patients.
Su WT; Chen JY; Sun JB; Huang QI; Ke ZB; Chen SH; Lin YZ; Xue XY; Wei Y; Xu N
J Biosci; 2024; 49():. PubMed ID: 38186002
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.
Cai H; Chen H; Huang Q; Zhu JM; Ke ZB; Lin YZ; Zheng QS; Wei Y; Xu N; Xue XY
Pathol Oncol Res; 2021; 27():1609941. PubMed ID: 34776794
[No Abstract] [Full Text] [Related]
3. A novel CD8
Lin F; Ke ZB; Xue YT; Chen JY; Cai H; Lin YZ; Li XD; Wei Y; Xue XY; Xu N
Inflamm Res; 2023 Aug; 72(8):1665-1687. PubMed ID: 37578544
[TBL] [Abstract][Full Text] [Related]
4. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
5. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
6. Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner.
Zhang Y; Xie Y; Feng Y; Wang Y; Xu X; Zhu S; Xu F; Feng N
Gene; 2022 Jan; 808():145966. PubMed ID: 34530089
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of tumor-infiltrating lymphocyte-related prognosis signature for predicting prognosis and immunotherapeutic response in bladder cancer.
Li C; Xie W
BMC Bioinformatics; 2023 Mar; 24(1):118. PubMed ID: 36973645
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide screening of abberant methylated drivers combined with relative risk loci in bladder cancer.
Zhang C; Shen K; Zheng Y; Qi F; Luo J
Cancer Med; 2020 Jan; 9(2):768-782. PubMed ID: 31794632
[TBL] [Abstract][Full Text] [Related]
9. Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
Shen C; Bi Y; Chai W; Zhang Z; Yang S; Liu Y; Wu Z; Peng F; Fan Z; Hu H
BMC Med Genomics; 2023 Oct; 16(1):264. PubMed ID: 37880682
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a molecular prognostic index of bladder cancer based on immunogenomic landscape analysis.
Xu N; Ke ZB; Lin XD; Chen YH; Wu YP; Chen Y; Dong RN; Chen SH; Li XD; Wei Y; Zheng QS; Lin YZ; Xue XY
Cancer Cell Int; 2020; 20():302. PubMed ID: 32675942
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
[TBL] [Abstract][Full Text] [Related]
12. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
13. Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555612
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Signature Development on the Basis of Macrophage Phagocytosis-Mediated Oxidative Phosphorylation in Bladder Cancer.
Qu G; Xu Y; Lu Z; Nie H; Tang C; Hou J; Wen X
Oxid Med Cell Longev; 2022; 2022():4754935. PubMed ID: 36211821
[TBL] [Abstract][Full Text] [Related]
15. Construction and Validation of a Prognostic Model Based on Pyroptosisrelated Genes in Bladder Cancer.
Shen C; Han C; Li Z; Yan Y; Li C; Chen H; Fan Z; Hu H
Comb Chem High Throughput Screen; 2023 Oct; ():. PubMed ID: 37849225
[TBL] [Abstract][Full Text] [Related]
16. Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response.
Xu W; Anwaier A; Ma C; Liu W; Tian X; Palihati M; Hu X; Qu Y; Zhang H; Ye D
Ann Med; 2021 Dec; 53(1):596-610. PubMed ID: 33830879
[TBL] [Abstract][Full Text] [Related]
17. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.
Ke ZB; You Q; Sun JB; Zhu JM; Li XD; Chen DN; Su L; Zheng QS; Wei Y; Xue XY; Xu N
Front Cell Dev Biol; 2021; 9():774625. PubMed ID: 35071228
[No Abstract] [Full Text] [Related]
18. A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.
Wang W; Zhang X; Jiang S; Xu P; Chen K; Li K; Wang F; Le X; Zhang K
Front Immunol; 2023; 14():1187286. PubMed ID: 37691944
[TBL] [Abstract][Full Text] [Related]
19. THBS1, a fatty acid-related metabolic gene, can promote the development of laryngeal cancer.
Ji FH; Qiu XG
Sci Rep; 2022 Nov; 12(1):18809. PubMed ID: 36335208
[TBL] [Abstract][Full Text] [Related]
20. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
Front Immunol; 2022; 13():967277. PubMed ID: 36466837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]